JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Adverum Biotechnologies Inc

Gesloten

SectorGezondheidszorg

4.05 -2.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.02

Max

4.22

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+170.27% upside

Dividenden

By Dow Jones

Volgende Winsten

31 okt 2025

Nieuwssentiment

By Acuity

81%

19%

344 / 371 Rangschikking in Healthcare

Adverum Biotechnologies Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 13:04 UTC

Acquisities, Fusies, Overnames

Eli Lilly Agrees to Acquire Adverum Biotechnologies

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY

24 okt 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY

24 okt 2025, 12:30 UTC

Acquisities, Fusies, Overnames

Lilly To Acquire Adverum Biotechnologies >LLY ADVM

Peer Vergelijking

Prijswijziging

Adverum Biotechnologies Inc Prognose

Koersdoel

By TipRanks

170.27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11 USD  170.27%

Hoogste 30 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Adverum Biotechnologies Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Sentiment

By Acuity

344 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

$

help-icon Live chat